Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Oct 14 (Reuters) — Zealand Pharma A/S: Said On Tuesday Zealand Pharma And Generate Biomedicines Enter Collaboration And License Agreement To Develop Protein Therapeutics Engineered With Ai For Metabolic Diseases Zealand: Generate Will Receive Usd 30 Million Up-front, Up To Usd 35 Million In Early Preclinical Milestones
Generate Biomedicines Inc: Generate Biomedicines And Zealand Pharma Enter Collaboration And License Agreement To Develop Protein Therapeutics Engineered With Ai For Metabolic Diseases Generate Biomedicines - To Receive $30 Million Upfront, Up To $1.20 Billion In Milestones, Plus Royalties Generate Biomedicines - Collab
The agreement covers development of AI-engineered protein therapeutics for metabolic diseases.